American Board of Family Medicine (ABFM) Practice Exam 2025 – The All-In-One Guide to Master Your Certification!

Thiazolidinediones (TZDs), a class of medications used primarily to manage type 2 diabetes, can lead to fluid retention, which is an important consideration in patient management. The primary mechanism behind this fluid retention is increased sodium retention. TZDs activate peroxisome proliferator-activated receptor-gamma (PPAR-γ), which plays a role in the regulation of fat cell differentiation and glucose metabolism, but also influences renal handling of sodium.

This sodium retention results in increased extracellular fluid volume, leading to edema and weight gain in some patients. This is particularly significant in individuals who have pre-existing conditions such as congestive heart failure, where fluid overload could exacerbate health issues.

The other options, while relevant to specific medical contexts, do not directly relate to the mechanism of fluid retention seen with TZD use. Systemic infection may lead to fluid shifts and retention but is not a common cause associated with the pharmacological effects of TZDs. Hormonal imbalance can cause fluid retention in a broader sense, but it is not specific to the action of TZDs. Similarly, increased vascular permeability relates more to inflammatory processes or allergic reactions and does not explain the sodium retention mechanism formed by TZD activity.